COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT
The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.
The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.
MEMBERS OF THE BOARD:
 |
 |
 |
 |
| Ken Newport Chair, Board of Directors |
Dr. Lorne Babiuk Vice-President, Research, University of Alberta |
Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa |
Ela Borenstein Program Director Business Development Bank of Canada (BDC) |
 |
 |
 |
 |
| Dr. Elizabeth Douville Founder and Managing Partner, AmorChem Venture Fund |
Craig Earle Vice-President, Cancer Control at the Canadian Partnership Against Cancer |
Karimah Es Sabar Chief Executive Officer & Partner, Quark Venture Inc. | Debra Lynkowski Chief Operating Officer The Ottawa Hospital Research Institute |
 |
 |
 |
 |
| Kendra MacDonald Partner, Deloitte |
Brian J. Underdown, Ph.D. Venture Partner, Lumira Capital |
Dr. Christine Williams Deputy Director, Ontario Institute for Cancer Research (OICR) |
Russell Williams Vice President, Government Relations and Public Policy, Diabetes Canada and Special Counsel, The JBL Group |
EX-OFFICIO MEMBERS (NON-VOTING)
 |
| Dr. Stéphanie Michaud President and CEO, BioCanRx Secretary, Board of Directors |
OBSERVERS
 |
| Alex Pigeon Senior Program Manager, Networks of Centres of Excellence |
